Wen-Kai Weng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11729308/publications.pdf

Version: 2024-02-01

49 papers	3,818 citations	377584 21 h-index	340414 39 g-index
49 all docs	49 docs citations	49 times ranked	4735 citing authors

#	Article	IF	Citations
1	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transplantation and Cellular Therapy, 2022, 28, 215.e1-215.e10.	0.6	11
2	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy, 2022, , .	0.6	3
3	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CARâ€“refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	0.6	51
4	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 2021, 5, 143-155.	2.5	92
5	Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. Cancer Investigation, 2021, , 1-11.	0.6	0
6	Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 405.e1-405.e6.	0.6	4
7	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation, 2021, 56, 2664-2671.	1.3	9
8	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	15.2	273
9	NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS. Journal of the American Academy of Dermatology, 2021, , .	0.6	0
10	Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. Blood, 2021, 138, 3885-3885.	0.6	2
11	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. Blood, 2021, 138, 741-741.	0.6	4
12	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. Blood, 2020, 136, 11-12.	0.6	0
13	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. Blood, 2020, 136, 22-23.	0.6	0
14	Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. Practical Radiation Oncology, 2019, 9, 220-225.	1.1	4
15	Gain of CD26 expression on the malignant Tâ€cells in relapsed erythrodermic leukemic mycosis fungoides. Journal of Cutaneous Pathology, 2017, 44, 462-466.	0.7	2
16	Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation. Journal of the American Academy of Dermatology, 2017, 77, 706-712.	0.6	22
17	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation, 2015, 50, 1004-1006.	1.3	1
18	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and SÃ©zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology, 2015, 33, 3750-3758.	0.8	235

#	Article	IF	Citations
19	A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 1878-1880.	0.6	4
20	Total Lymphoid Irradiationâ€“Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2014, 20, 837-843.	2.0	18
21	Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 2014, 124, 2668-2682.	3.9	154
22	Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and SÃ©zary Syndrome (SS). Blood, 2014, 124, 2544-2544.	0.6	15
23	Use of High-Throughput Sequencing (HTS) of TCRÃŸ to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant. Blood, 2014, 124, 2473-2473.	0.6	0
24	Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. Science Translational Medicine, 2013, 5, 214ra171.	5.8	84
25	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood, 2012, 119, 6145-6154.	0.6	107
26	Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. Journal of Clinical Investigation, 2012, 122, 1066-1075.	3.9	202
27	Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1679-1687.	2.0	125
28	Immunoglobulin G Fc Receptor FcÎ³RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 279-284.	0.8	112
29	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 37-46.	0.6	39
30	Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leukemia and Lymphoma, 2009, 50, 1494-1500.	0.6	31
31	Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leukemia and Lymphoma, 2009, 50, 723-727.	0.6	32
32	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood, 2009, 114, 1099-1109.	0.6	150
33	A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.. Blood, 2009, 114, 3304-3304.	0.6	0
34	A Polymorphism in the Complement ComponentC1qACorrelates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. Clinical Cancer Research, 2008, 14, 6697-6703.	3.2	149
35	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood, 2008, 112, 711-720.	0.6	97
36	Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood, 2007, 109, 951-953.	0.6	34

#	Article	IF	Citations
37	Rituximab Variants with Re-Engineered Fc with Higher Affinity to Activating FcÎ³ R Eliminate the Functional Difference between FcÎ³ R Genotypes.. Blood, 2005, 106, 347-347.	0.6	5
38	A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.. Blood, 2005, 106, 778-778.	0.6	3
39	Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype Are Associated with Better Clinical Outcome Following Idiotype Vaccination in Follicular Lymphoma Patients Regardless of Their Response to Induction Chemotherapy.. Blood, 2005, 106, 777-777.	0.6	0
40	A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.. Blood, 2005, 106, 2964-2964.	0.6	0
41	Use of Dendritic Cells and GM-CSF Adjuvant Are Associated with Anti-Idiotype Cellular Immune Response Following Idiotype Vaccination in Follicular Lymphoma Patients.. Blood, 2005, 106, 771-771.	0.6	1
42	Genetic Polymorphism of the Inhibitory IgG Fc Receptor FcÎ³RIIb Is Not Associated with Clinical Outcome of Rituximab Treated Follicular Lymphoma Patients.. Blood, 2005, 106, 2430-2430.	0.6	1
43	Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype. Journal of Clinical Oncology, 2004, 22, 4717-4724.	0.8	190
44	A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkinâ€™s Lymphoma.. Blood, 2004, 104, 3279-3279.	0.6	5
45	Immunoglobulin G Fc Polymorphism Is Correlated with Rituximab-Induced Neutropenia Following Autologous Hematopoietic Cell Transplantation.. Blood, 2004, 104, 442-442.	0.6	3
46	Immunoglobulin G Fc Receptor Polymorphisms and Clinical Course in Follicular Lymphoma Patients.. Blood, 2004, 104, 3250-3250.	0.6	0
47	Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma. Journal of Clinical Oncology, 2003, 21, 3940-3947.	0.8	1,245
48	Hepatitis C Virus (HCV) and Lymphomagenesis. Leukemia and Lymphoma, 2003, 44, 1113-1120.	0.6	92
49	Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 2001, 98, 1352-1357.	0.6	207